Feb 28 (Reuters) - Biopharmaceutical company XenoPort Inc (XNPT.O) and British drugmaker GlaxoSmithKline (GSK.L) (GSK.N) said its drug to treat restless legs syndrome met the main goals in a late-stage trial.
The companies plan to file for marketing approval for the drug, XP13512, in the third quarter. (Reporting by Jennifer Robin Raj in Bangalore; Editing by Pratish Narayanan)
KAILUA, Hawaii (Reuters) - A wing of al Qaeda claimed responsibility on Monday for a failed Christmas Day attack on a U.S.-bound passenger plane and President Barack Obama vowed to bring "every element" of U.S. power against those who threaten Americans' safety. | Video
The U.S. is stepping up airline security measures following the Christmas bomb scare. Here's what you can expect. Full Article | Video
Is Iran's "iron fist of brutality" a new volatile phase aimed at crushing the refomist movement? Full Article | Video
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
